Within part I, cohorts A, B, and C started at progressively higher doses (100 mg, 200 mg, or 300 mg), all rising to 600 mg bid, in order to explore the optimal titration schedule; cohort D evaluated cerebrospinal fluid (CSF) pharmacokinetics at the

lower end of the dosing range (at 100 and 300 mg bid). The treatment duration in part I was between 10 and 16 days, depending on the titration schedule. Part II was a 30-patient, randomized, double-blind, parallel-group, placebo-controlled design, which evaluated two dose levels of Org 26576 for 28 days (10 subjects assigned to 100 mg bid, 10 subjects assigned to 400 mg bid, and 10 subjects assigned to placebo), with objectives to evaluate tolerability, pharmacokinetics,

and Ferroptosis inhibitor clinical trial pharmacodynamics over an extended treatment period. The doses in part II were selected on the basis of the tolerability results from part I. All selected patients were male or female, aged 18–65 years, and diagnosed with MDD according to the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). Current depressive episodes were mild to severe without psychotic features, and no more than 2 years in duration, with a total score of at least FK228 clinical trial 9 but not more than 20 on the Quick Inventory of Depression Symptomatology – Clinician Rating (QIDS-C).[31] Patients who had received antidepressant treatment with an adequate dose and duration in the current episode were excluded. Eligible patients were otherwise generally healthy and medically stable; were taking no concurrent psychotropic medications; and had no history of bipolar disorder, psychosis, Molecular motor post-traumatic stress disorder, obsessive-compulsive disorder, or eating disorder. Patients with a 6-month history of substance

dependence (not including nicotine), current substance abuse, or a positive screening or admission urine drug/alcohol test were excluded. Subjects in both trials were admitted to the unit 1–2 days before the first dosing and confined for the full term of the dosing period. Diet and physical activity were controlled, and subjects were closely monitored for safety and tolerability. Safety evaluations included regular AE assessments, vital signs, 12-lead electrocardiograms (ECGs), clinical laboratory assessments, and safety electroencephalograms (EEGs) conducted in a resting state with eyes open and closed, with photic stimulation, and with 3 minutes of hyperventilation. In addition, the patient trial included frequent suicidality assessment using the Beck Scale for Suicidal Ideation (BSS).[32] In study 1, the MTD was not specifically defined a priori; however, safety and tolerability were closely monitored by the study investigators and the sponsor in a blinded fashion, and dosing progression was largely dependent on absence of medication discontinuations due to AEs.